Role of Old Antibiotics in the Era of Antibiotic Resistance. Highlighted Nitrofurantoin for the Treatment of Lower Urinary Tract Infections

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2016 Mar 31

PMID 27025732

Citations 19

Authors

Maria Jose Munoz-Davila

Affiliations

Soon will be listed here.

Abstract

Bacterial infections caused by antibiotic-resistant isolates have become a major health problem in recent years, since they are very difficult to treat, leading to an increase in morbidity and mortality. Nitrofurantoin is a broad-spectrum bactericidal antibiotic that, through a complex mode of action which is not completely understood, affects both Gram-negative and Gram-positive bacteria. Nitrofurantoin has been used successfully for a long time for the prophylaxis and treatment of acute lower urinary tract infections in adults, children and pregnant women, but the increased emergence of antibiotic resistance has made nitrofurantoin a suitable candidate for the treatment of infections caused by multidrug-resistant pathogens. Here, we review the mechanism of action, antimicrobial spectrum, pharmacology and safety profile of nitrofurantoin. We also investigate the therapeutic use of nitrofurantoin, including recent data which highlight its role in the management of community urinary tract infection, especially in cases of multidrug-resistant isolates, in which oral active antimicrobials are limited resources nowadays.

Citing Articles

Perturbation-specific transcriptional mapping for unbiased target elucidation of antibiotics.

Romano K, Bagnall J, Warrier T, Sullivan J, Ferrara K, Orzechowski M Proc Natl Acad Sci U S A. 2024; 121(45):e2409747121.

PMID: 39467118 PMC: 11551328. DOI: 10.1073/pnas.2409747121.

Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity.

Vinogradova L, Lukin A, Komarova K, Zhuravlev M, Fadeev A, Chudinov M Molecules. 2024; 29(14).

PMID: 39064943 PMC: 11279955. DOI: 10.3390/molecules29143364.

Design, Synthesis, and In Vitro and In Vivo Bioactivity Studies of Hydrazide-Hydrazones of 2,4-Dihydroxybenzoic Acid.

Popiolek L, Gawronska-Grzywacz M, Dziduch A, Biernasiuk A, Piatkowska-Chmiel I, Herbet M Int J Mol Sci. 2023; 24(24).

PMID: 38139308 PMC: 10743905. DOI: 10.3390/ijms242417481.

Fluoroquinolone resistance determinants in carbapenem-resistant isolated from urine clinical samples in Thailand.

Boueroy P, Chopjitt P, Hatrongjit R, Morita M, Sugawara Y, Akeda Y PeerJ. 2023; 11:e16401.

PMID: 37953793 PMC: 10638923. DOI: 10.7717/peerj.16401.

Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review.

Mahdizade Ari M, Dashtbin S, Ghasemi F, Shahroodian S, Kiani P, Bafandeh E Front Cell Infect Microbiol. 2023; 13:1148603.

PMID: 37577377 PMC: 10414118. DOI: 10.3389/fcimb.2023.1148603.

References

Cunha B, Schoch P, Hage J . Oral therapy of catheter-associated bacteriuria (CAB) in the era of antibiotic resistance: nitrofurantoin revisited. J Chemother. 2012; 24(2):122-4. DOI: 10.1179/1120009X12Z.00000000013. View

Kahlmeter G . An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2002; 51(1):69-76. DOI: 10.1093/jac/dkg028. View

Talan D, Stamm W, Hooton T, Moran G, Burke T, Iravani A . Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000; 283(12):1583-90. DOI: 10.1001/jama.283.12.1583. View

Sorlozano Puerto A, Gutierrez Fernandez J, Luna Del Castillo J, Soto Pino M, Piedrola Angulo G . In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis. 2006; 54(2):135-9. DOI: 10.1016/j.diagmicrobio.2005.08.018. View

Fadda G, Nicoletti G, Schito G, Tempera G . Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother. 2005; 17(3):251-7. DOI: 10.1179/joc.2005.17.3.251. View

Zhanel G, Hisanaga T, Laing N, DeCorby M, Nichol K, Weshnoweski B . Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006; 27(6):468-75. DOI: 10.1016/j.ijantimicag.2006.02.009. View

Crider K, Cleves M, Reefhuis J, Berry R, Hobbs C, Hu D . Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009; 163(11):978-85. DOI: 10.1001/archpediatrics.2009.188. View

Holmberg L, Boman G, BOTTIGER L, Eriksson B, Spross R, Wessling A . Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med. 1980; 69(5):733-8. DOI: 10.1016/0002-9343(80)90443-x. View

SACHS J, Geer T, Noell P, Kunin C . Effect of renal function on urinary recovery of orally administered nitrofurantoin. N Engl J Med. 1968; 278(19):1032-5. DOI: 10.1056/NEJM196805092781902. View

10.

Lee M, Bozzo P, Einarson A, Koren G . Urinary tract infections in pregnancy. Can Fam Physician. 2008; 54(6):853-4. PMC: 2426978. View

11.

Gupta K, Hooton T, Roberts P, Stamm W . Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med. 2007; 167(20):2207-12. DOI: 10.1001/archinte.167.20.2207. View

12.

Hailey F, Fort H, Williams J, Hammers B . Foetal safety of nitrofurantoin macrocrystals therapy during pregnancy: a retrospective analysis. J Int Med Res. 1983; 11(6):364-9. DOI: 10.1177/030006058301100608. View

13.

Hosbach R, Foster R . Absence of nitrofurantoin from human milk. JAMA. 1967; 202(11):1057. View

14.

Cunha B . New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am. 2006; 90(6):1089-107. DOI: 10.1016/j.mcna.2006.07.006. View

15.

CONKLIN J . The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiot Chemother (1971). 1978; 25:233-52. DOI: 10.1159/000401065. View

16.

Procop G, Tuohy M, Wilson D, Williams D, Hadziyannis E, Hall G . Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am J Clin Pathol. 2003; 120(2):265-7. DOI: 10.1309/EF69-VNDL-VPWV-E4QV. View

17.

Schneeberger C, Geerlings S, Middleton P, Crowther C . Interventions for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst Rev. 2012; 11:CD009279. DOI: 10.1002/14651858.CD009279.pub2. View

18.

Honderlick P, Cahen P, Gravisse J, Vignon D . [Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?]. Pathol Biol (Paris). 2006; 54(8-9):462-6. DOI: 10.1016/j.patbio.2006.07.016. View

19.

Guinto V, De Guia B, Festin M, Dowswell T . Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2010; (9):CD007855. PMC: 4033758. DOI: 10.1002/14651858.CD007855.pub2. View

20.

PRYTHERCH J, Sutton M, Denine E . General reproduction, perinatal-postnatal, and teratology studies of nitrofurantoin macrocrystals in rats and rabbits. J Toxicol Environ Health. 1984; 13(4-6):811-23. DOI: 10.1080/15287398409530542. View